Editorial - Journal of Experimental Stroke & Translational Medicine (2025) Volume 17, Issue 2
Pharmacogenomics: Personalizing Medicine Through Genetic Insights
Marcus Lee*
Department of Clinical Pharmacology, University of Melbourne, Australia
- *Corresponding Author:
- Marcus Lee
Department of Clinical Pharmacology, University of Melbourne, Australia
E-mail: marcus.lee@unimelb.edu.au
Received: 01-March-2025, Manuscript No. jestm-25-170399; Editor assigned: 3-March-2025, PreQC No. jestm-25-170399 (PQ); Reviewed: 17-March-2025, QC No. jestm-25-170399; Revised: 24-March-2025, Manuscript No. jestm-25-170399 (R); Published: 31-March-2025, DOI: 10.37532/jestm.2024.16(6).327-328
Introduction
The traditional model of prescribing medications often follows a “one-size-fits-all” approach, where treatments are chosen based on population-level data rather than individual differences. However, patients frequently respond differently to the same drug—some achieve the desired therapeutic effect, others experience minimal benefit, and a subset may suffer from severe side effects. These variations are increasingly understood to be rooted in genetics [1].
Pharmacogenomics, the study of how genes influence an individual’s response to drugs, is a cornerstone of precision medicine. By integrating genetic insights into prescribing practices, pharmacogenomics promises to optimize drug efficacy, reduce adverse reactions, and improve overall patient outcomes.
Foundations of Pharmacogenomics
Pharmacogenomics explores the relationship between genetic variation and pharmacokinetics (how the body processes drugs) as well as pharmacodynamics (how drugs affect the body). Key elements include:
Drug Metabolism Genes: Variants in cytochrome P450 enzymes (e.g., CYP2D6, CYP2C19) significantly affect metabolism of common drugs, including antidepressants, anticoagulants, and opioids.
Drug Transporters: Genes encoding transport proteins, such as ABCB1, influence drug absorption and distribution.
Drug Targets: Variations in genes encoding receptors or enzymes can alter drug binding and therapeutic response.
Immune-Related Genes: Certain alleles, such as HLA-B*57:01, are associated with severe hypersensitivity reactions to drugs like abacavir.
By identifying these genetic determinants, clinicians can predict how patients are likely to respond to specific medications.
Clinical Applications of Pharmacogenomics
Oncology: Cancer treatment has been one of the earliest and most impactful applications. Genetic profiling of tumors guides the use of targeted therapies, such as HER2 inhibitors in breast cancer or EGFR inhibitors in lung cancer.
Cardiology: Pharmacogenomics informs the use of anticoagulants. For example, variants in CYP2C9 and VKORC1 affect metabolism and dosing of warfarin [2], helping reduce the risk of bleeding complications.
Psychiatry: Antidepressant and antipsychotic medications often have variable efficacy and side effects. Pharmacogenomic testing for CYP450 variants supports more informed prescribing, reducing the trial-and-error process.
Infectious Diseases: Testing for HLA-B*57:01 before prescribing abacavir prevents life-threatening hypersensitivity reactions in HIV patients. Similarly, pharmacogenomics helps optimize treatment for hepatitis C and tuberculosis.
Pain Management: Genetic variation in opioid metabolism (e.g., CYP2D6 ultrarapid metabolizers) influences both effectiveness and risk of toxicity, guiding safer opioid prescribing.
Benefits of Pharmacogenomics
Improved Efficacy: Aligns therapy with patients’ genetic profiles for better outcomes.
Reduced Adverse Events: Prevents harmful side effects by avoiding incompatible drugs.
Cost Savings: Reduces trial-and-error prescribing, unnecessary hospitalizations, and ineffective treatments [3].
Patient Empowerment: Provides individuals with personalized insights into their medication options.
Challenges and Limitations
While pharmacogenomics is advancing rapidly, several challenges remain:
Data Interpretation: Many variants of uncertain significance complicate clinical application [4].
Access and Cost: Genetic testing remains expensive and is not universally covered by healthcare systems.
Population Diversity: Most pharmacogenomic data are derived from European populations, limiting applicability across global populations.
Ethical and Privacy Concerns: Genetic data must be carefully safeguarded to prevent misuse or discrimination.
Clinical Integration: Incorporating pharmacogenomic testing into routine practice requires clinician training, electronic health record integration, and updated prescribing guidelines.
Future Perspectives
The future of pharmacogenomics is closely tied to technological innovation and healthcare integration:
Next-Generation Sequencing: Whole-genome sequencing will provide comprehensive pharmacogenomic profiles at decreasing costs.
Artificial Intelligence: Machine learning will enable integration of genomic, clinical, and lifestyle data for predictive prescribing models.
Population Databases: Expanding global genomic datasets will enhance diversity and equity in pharmacogenomic research [5].
Routine Clinical Practice: As testing becomes more accessible, pharmacogenomic data may be included in every patient’s medical record to guide lifelong prescribing decisions.
Ultimately, pharmacogenomics will evolve from being applied in specialized contexts—such as oncology—to becoming a standard part of everyday medicine.
Conclusion
Pharmacogenomics represents a paradigm shift in healthcare, transforming drug prescribing from a population-based approach to one tailored to individual genetic profiles. By predicting efficacy and adverse effects, it enhances treatment safety, effectiveness, and efficiency. Although challenges related to cost, equity, and clinical implementation remain, rapid technological and scientific progress promises to overcome these barriers. As pharmacogenomics becomes more integrated into healthcare systems worldwide, it will play a central role in realizing the vision of truly personalized medicine.
References
- Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, et al. (2013) Bariatric surgery versus non-surgical treatment for obesity: A systematic review and meta-analysis of randomized controlled trials. BMJ 347: f5934.
- Sharma AM, Kushner RF (2020) A proposed clinical staging system for obesity. Int J Obes (Lond) 44: 382-387.
- Dixon JB, Zimmet P, Alberti KG, Rubino F (2016) Bariatric surgery: an IDF statement for obese Type 2 diabetes. Surg Obes Relat Dis 7: 433-447.
- Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. (2017) Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 377: 13-27.
- Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL (2016) Trends in obesity among adults in the United States, 2005 to 2014. JAMA 315(21): 2284-2291.
